ArticleTrials2026
Efficacy of ultraviolet germicidal irradiation (UVGI) devices to decrease the incidence of respiratory infections in nursing homes: study protocol for a cluster randomized crossover trial (RESPROTECT).
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06569160 (Impact du déploiement de Dispositifs d'Inactivation Des pathogènes de l'Air Par UVGI Dans la Lutte Contre Les Maladies Respiratoires Touchant Les résidents d'EHPAD), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact du déploiement de Dispositifs d'Inactivation Des pathogènes de l'Air Par UVGI Dans la Lutte Contre Les Maladies Respiratoires Touchant Les résidents d'EHPAD
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundUltraviolet germicidal irradiation (UVGI) has long been recognized for its ability to inactivate airborne pathogens under experimental conditions. However, despite strong in vitro evidence, randomized clinical evidence of its real-world effectiveness remains lacking. Nursing homes-where respiratory infections are a major cause of morbidity and mortality-represent a highly relevant setting to evaluate the preventive potential of UVGI. The RESPROTECT trial aims to assess whether continuous UVGI use in communal areas of nursing homes reduces the incidence of severe acute respiratory infections (ARIs) among residents.
methodsRESPROTECT is a multicenter, open cohort, quadruple-blind, cluster-randomized, crossover trial. A total of 848 UVGI devices were installed in communal living areas of 12 nursing homes in the Haute-Loire region, France. All devices are switched on, but some contain internal filters that deactivate UV light while remaining indistinguishable from the outside. Centers were randomized 1:1 into two groups: unfiltered UVGI devices active during period 1 (October 2024-April 2025), then filtered (inactive) during period 2 (October 2025-April 2026), or the reverse sequence. The primary outcome is the incidence of severe ARIs. Secondary outcomes include the incidence of ARIs of any grade, all-cause hospitalization or death, adverse events of interest (keratitis and erythema), antibiotic consumption, airborne and surface pathogen loads, and cost-effectiveness. All analyses will follow the intention-to-treat principle and use mixed-effects Poisson regression models with fixed effects for period and random effects for clusters, cluster-periods and individuals. DISCUSSION: RESPROTECT is one of the first large-scale blinded randomized trials to evaluate the clinical effectiveness of UVGI in preventing respiratory infections among elderly residents in nursing homes. It will complement recent findings from the PETRA trial (JAMA Intern Med 2025) and is designed to provide robust data on both clinical outcomes and environmental contamination. If UVGI proves effective, it could represent a practical, low-maintenance, and scalable infection-prevention strategy for high-risk institutional settings.
trial registrationFrench RCB identifier: RECHMIE-22-0003 - 2024-A00199-38. CLINICALTRIALS: gov Identifier: NCT06569160 (Registered on August 21, 2024). https://clinicaltrials.gov/study/NCT06569160 .
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.